Curated News
By: NewsRamp Editorial Staff
September 22, 2026
Quantum BioPharma Pursues New Path for Multiple Sclerosis Treatments
TLDR
- Quantum BioPharma's Lucid-MS targets an unmet need in progressive MS, offering a potential first-in-class therapy in a market with nearly three million patients.
- Lucid-MS inhibits peptidyl arginine deiminase 2 to directly block demyelination, addressing neurodegeneration that current therapies cannot reverse.
- Quantum BioPharma's Lucid-MS aims to reverse disability in multiple sclerosis, offering hope for a better quality of life to millions worldwide.
- Multiple sclerosis affects nearly three million people globally, and Quantum BioPharma's Lucid-MS takes a novel approach by targeting an enzyme to prevent myelin damage.
Impact - Why it Matters
This news matters because multiple sclerosis affects nearly three million people globally, yet no current therapy reverses the neurodegeneration that causes long-term disability. Quantum BioPharma’s Lucid-MS, which targets an enzyme involved in demyelination, could offer a first-in-class approach for progressive forms of MS. If successful, it would fill a critical gap in treatment options, potentially slowing or stopping disease progression and improving quality of life for patients. For investors, it represents a high-reward opportunity in a space with substantial unmet need and growing prevalence.
Summary
Nearly three million people worldwide are living with multiple sclerosis, a chronic disease in which the immune system attacks myelin, the protective coating around nerve fibers. In the United States alone, close to one million people are affected, more than double previous estimates. With no cure and no approved therapy that directly reverses the neurodegeneration driving long-term disability, new approaches are urgently needed. That’s where Quantum BioPharma (NASDAQ: QNTM) is focusing its efforts with its lead drug candidate, Lucid-MS. The experimental treatment is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2, potentially offering a novel mechanism for progressive forms of MS that have remained especially elusive to treat.
The global prevalence of MS rose from about 2.3 million people in 2013 to nearly three million today, underscoring the growing burden of the disease. While existing therapies can modify the immune response, they do not stop or reverse the underlying nerve damage. Quantum BioPharma’s approach aims to protect myelin and thereby slow or halt disability progression, a goal that has frustrated researchers for decades. The company’s work is being highlighted by BioMedWire, a specialized communications platform focused on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications services to reach investors, journalists, and the public.
For investors and patients alike, the development of Lucid-MS represents a potential breakthrough in a field where innovation has been slow. If successful, it could address a significant unmet need and improve the lives of millions. The latest updates on QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Pursues New Path for Multiple Sclerosis Treatments
